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Abstract: The origin of vascular smooth muscle cells that accumulate in the neointima in vascular diseases such as trans-
plant arteriosclerosis, atherosclerosis and restenosis remains subject to much debate. Smooth muscle cells are a highly 
heterogeneous cell population with different characteristics and markers, and distinct phenotypes in physiological and 
pathological conditions. Several studies have reported a role for bone marrow-derived progenitor cells in vascular mainte-
nance and repair. Moreover, bone marrow-derived smooth muscle progenitor cells have been detected in human athero-
sclerotic tissue as well as in in vivo mouse models of vascular disease. However, it is not clear whether smooth muscle 
progenitor cells can be regarded as a ‘friend’ or ‘foe’ in neointima formation. In this review we will discuss the heteroge-
neity of smooth muscle cells, the role of smooth muscle progenitor cells in vascular disease, potential mechanisms that 
could regulate smooth muscle progenitor cell contribution and the implications this may have on designing novel thera-
peutic tools to prevent development and progression of vascular disease.  
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INTRODUCTION 
  Vascular smooth muscle cells (SMC) are highly special-
ized cells whose principal function is contraction and regula-
tion of blood vessel tone-diameter, blood pressure, and blood 
flow distribution [1]. However, SMC also play an important 
role in vessel wall pathology. The accumulation of SMC in 
the intima accompanies vascular diseases such as atheroscle-
rosis, restenosis after angioplasty or stent placement and 
transplant arteriosclerosis and is therefore an important 
therapeutic target. In order to create novel therapeutic tools 
to prevent this, insight into the origin of SMC is essential. 
Both during embryonic development as well as in the devel-
opment of vascular pathologies SMC originate from diverse 
sources. With regard to intimal SMC the longstanding theory 
is that changes in the environment lead to the migration of 
SMC from the media to the intima. However, other possible 
sources include adventitial fibroblasts or endothelial cells. 
Recent reports have indicated a role for bone marrow (BM)-
derived smooth muscle progenitor cells (SPC) that can con-
tribute to development and progression of vascular disease 
[2-5]. In this review we will discuss the heterogeneity of 
SMC, the role of SPC in neointima formation, possible 
mechanisms that could regulate SPC contribution and their 
potential as a target for new therapeutic strategies to prevent 
disease.  
VASCULAR SMC IN HEALTH AND DISEASE 
  SMC are highly specialized cells that comprise the main 
component of the media of the vessel wall. Their principal 
physiological function is to maintain vasomotor tone via 
contraction or relaxation in response to a variety of meta-
bolic and hormonal stimuli, as well as vessel integrity by   
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proliferation and synthesis of extracellular matrix [6, 7]. Dif-
ferentiated SMC are unique compared with other cell types 
as they display a low rate of proliferation, low synthetic ac-
tivity, and express a unique repertoire of contractile proteins, 
ion channels, and signaling molecules required for the cell’s 
contractile function [7]. In contrast to either skeletal or car-
diac myocytes that are terminally differentiated, SMC retain 
remarkable plasticity and can undergo rather profound and 
reversible changes in phenotype in response to changes in 
local environmental cues [7]. SMC accumulation in the 
neointima is a common feature in vascular diseases such as 
atherosclerosis, restenosis and transplant arteriosclerosis 
contributing to cardiovascular morbidity and mortality.  
  Atherosclerosis is a chronic disease that progresses over 
years and comprises a complex interaction between lipids, 
endothelium, circulating and tissue inflammatory cells, plate-
lets and SMC. Inflammatory mediators produced by acti-
vated macrophages can lead to phenotypic switching of me-
dial SMC into a synthetic and migratory phenotype, which 
thereby form the fibrous component of the plaque. On the 
one hand, SMC contribute to plaque volume and stabiliza-
tion by producing extracellular matrix, on the other hand 
they contribute to plaque degradation and rupture by produc-
ing growth factors and enzymes [8, 9]. 
  Restenosis is a major problem after revascularization 
procedures such as angioplasty, stenting, and bypass graft-
ing, characterized by intimal SMC recruitment, accumulation 
and inward remodeling. The acute mechanical injury triggers 
a cascade of events that includes endothelial denudation, 
direct SMC trauma, and the subsequent release of multiple 
growth factors that all play a role in the phenotypic switch of 
SMC. Interaction between inflammatory cells, platelets and 
SMC leads to the production of extracellular matrix by SMC 
which constitutes the bulk of the intimal lesion that contrib-
utes to restenosis [10-12].  
  Transplant arteriosclerosis can occur after heterotopic 
transplantation of organs or vessels. It is a major limitation 132    Current Stem Cell Research & Therapy, 2009, Vol. 4, No. 2  Oostrom et al. 
of long-term survival of patients with solid organ transplan-
tation. An immune-mediated response to donor endothelial 
cells and SMC is thought to take place. This leads to the in-
filtration of recipient mononuclear cells in the vessel wall of 
grafts at an early stage which secrete inflammatory cytokines 
inducing the recruitment and activation of SMC. Neointimal 
formation progressively occludes the vascular lumen, com-
promising luminal flow and leading to ischemic tissue dam-
age [13, 14].  
  A diverse range of experimental animal models are used 
to study the role of SMC in vascular disease. The hyperlipi-
demia-induced mouse model develops spontaneous athero-
sclerosis which can be used in conjunction with a constric-
tive collar to accelerate and localize the development of le-
sions [15]. Restenosis is studied in animal models in which 
mechanical injury to the artery is induced by use of a wire, 
loose cuff or ligation [16]. Transplant arteriosclerosis in-
volves heterotopic transplantation of organs or vessels. Al-
though SMC recruitment and accumulation are a common 
feature of the above mentioned vascular pathologies, the 
mechanisms may differ according to the pathology and the 
cause and severity of injury. This is of importance when 
studying the characterization, origin and contribution of 
SMC to vascular disease in the different models.  
HETEROGENEITY OF VASCULAR SMC 
  The contemporary paradigm is that dysfunctional endo-
thelium and/or inflammatory cells produce growth factors, 
proteolytic agents, and extracellular matrix proteins that can 
induce migration of SMC from the media to the intima and 
promote the switch from a contractile to synthetic phenotype 
[8]. Studies on cytoskeletal and contractile protein expres-
sion in vascular development and disease have shown that 
expression of these genes is coordinately upregulated in dif-
ferentiated SMC and downregulated in proliferating SMC 
[1]. However, this concept has been challenged by other 
studies showing that plaque SMC can be monoclonal [17, 
18] or oligoclonal [19] suggesting that a predisposed SMC 
subpopulation is responsible for the production of intimal 
thickening. This indicates that SMC of the arterial wall could 
be biologically heterogeneous. Therefore, results may not be 
attributable to phenotypic variants of a single type of SMC, 
but reflect the activity of a mixture of different SMC sub-
types.  
  The description of contractile or synthetic phenotypes has 
contributed to the concept of SMC heterogeneity. In a ma-
ture blood vessel, medial SMC display a spindle-shaped con-
tractile or differentiated phenotype characterized by the ex-
pression of contractile proteins specific to smooth muscle, 
such as smooth muscle -actin (-SMA), smooth muscle 
myosin heavy chain (SM MHC), caldesmon, calponin, 
SM22 and smoothelin which are important for the regula-
tion of contraction in differentiated arteries [7, 12]. The most 
widely used SMC marker is -SMA which is expressed at 
even early stages of development, and thus represents the 
most general marker of SMC lineage. Although -SMA is 
permanently expressed in SMC, it is more abundant in con-
tractile SMC than in synthetic SMC. Furthermore, myofila-
ment bundles are abundant in the cytoplasm of the differen-
tiated cell whereas organelles, such as rough endoplasmatic 
reticulum, Golgi and free ribosomes are few in number [6]. 
The synthetic SMC is typical of developing and pathologic 
arteries, and is characterized by an increased rate of prolif-
eration, migration, and synthesis of extracellular matrix 
components. At the same time, synthetic SMC show a de-
crease in expression of smooth muscle-specific contractile 
markers [12]. Moreover, the cytoplasm contains large 
amounts of rough endoplasmatic reticulum, Golgi, and free 
ribosomes supporting its function in production of extracel-
lular matrix [6]. Although intimal SMC share some similari-
ties with medial SMC, studies have shown that they display 
several distinct characteristics regarding morphology, gene 
expression and synthetic properties [1, 20-22]. 
  Another concept of relevance to SMC heterogeneity is 
that during embryonic development vascular SMC arise 
from multiple sources. This is of interest as SMC from dif-
ferent lineages could be functionally distinct. In the embryo, 
vessels and even different segments of the same vessel are 
composed of SMC populations that arise from distinct pro-
genitors each with its own unique lineage. Studies have 
shown that there are eight origins from which SMC can be 
derived; neural crest, secondary heart field, somites, various 
stem cells, mesangioblasts, proepicardium, splanchnic meso-
derm and mesothelium [23]. A better understanding of the 
origins of SMC in development and vascular disease could 
provide important new insights in neointimal SMC and 
therefore in new therapeutic strategies.  
ORIGIN OF SMC IN VASCULAR DISEASE: ROLE 
OF BM-DERIVED SPC 
  The traditional theory is that SMC migrate from the me-
dia into the intima in response to environmental cues. How-
ever, recent studies have shown that other origins for SMC 
exist including the adventitial layer of the vessel wall, the 
endothelium and the BM. In 1997, Asahara et al. [24] re-
ported the existence and involvement of BM-derived endo-
thelial progenitor cells (EPC) in adult physiological and 
pathological vasculogenesis. This opened up a new field of 
research exploring the possibility that BM cells, depending 
on environmental cues, can differentiate into different cell 
types. Whereas the involvement of BM-derived EPC in ves-
sel repair and neovascularization has been acknowledged, 
the question whether BM is a source of SMC that contributes 
to neointima formation remains under debate (for an over-
view of studies see Table, Fig. 1).  
Variable Results of the Role of BM-Derived Cells in Vas-
cular Disease 
  Several studies have suggested that circulating BM-
derived cells contribute to neointima formation. In animal 
models of transplant arteriosclerosis including cardiac and 
aortic transplantation, SMC in the neointima have been 
shown to derive from host cells [2-4, 25-28]. Some of these 
studies, which involved BM-chimeric animals report that 
these cells are (in part) BM-derived [3, 4]. Heterotopic trans-
plantation of wild-type hearts into BM-chimeric mice 
showed that after four weeks most of the neointimal cells in 
the coronary arteries were BM-derived [3]. Other studies, on 
the other hand, report no evidence for a contribution of BM 
to the recipient cells in the neointimal layer [25-27]. In mice 
models of vein and artery graft atherosclerosis, SMC in inti-
mal lesions were reported to be derived from the recipients 
but not from BM-derived progenitor cells [26, 27].  Smooth Muscle Progenitor Cells  Current Stem Cell Research & Therapy, 2009, Vol. 4, No. 2      133 
Table 1.  Overview of Experimental Studies Investigating the Role of BM in Vascular Disease 
 
Experimental Study  Technique  Method to Determine  Time  Results  Reference 
  
SMC 
Origin 
SMC 
  Origin of 
Neointi-
mal SMC 
BM-Derived 
SMC 
 
mouse          
Transplant arterio-
sclerosis  
        
 Aortic  transplantation  Y-chr/ISH  -SMA/IH  30/60 days  Recipient  Few if any  Li et al. [25] 
 
Aortic transplantation 
LacZ/X-
gal stain-
ing 
-SMA/IH 8  weeks  Recipient  11% of intimal 
SMC 
Shimizu et al. 
[4] 
 
Aortic transplantation 
LacZ/X-
gal stain-
ing 
SM-LacZ trans-
genic/X-gal 
staining 
2-6  weeks  Recipient None Hu  et al. [26] 
 
Cardiac transplanta-
tion 
LacZ/X-
gal stain-
ing, 
GFP/IF 
staining 
-SMA/IF 4  weeks  Recipient 
(88%) 
Majority of inti-
mal SMC  Sata et al. [3] 
 
Vein graft transplanta-
tion 
LacZ/X-
gal stain-
ing 
SM-LacZ trans-
genic/X-gal 
staining 
8 weeks 
Recipient 
(40%) and 
donor 
(60%) 
None Hu  et al. [27] 
Atherosclerosis        
 
Hyperlipidemia-
induced atherosclero-
sis 
GFP/IF 
confocal, 
Y-chr/ISH 
-SMA/IH, Y-
chr/ISH 
Diet till 20 
weeks/32 
weeks of age 
NA None  Bentzon et al. 
[29] 
  Spontaneous and 
mechanical plaque 
disruption 
GFP/ IF 
confocal, 
Y-chr/ISH 
-SMA/IH, Y-
chr/ISH 
Up to 27 
months of 
age/after 1 or 
4 weeks 
NA None  Bentzon et al. 
[30] 
 
Hyperlipidemia-
induced atherosclero-
sis 
LacZ/X-
gal stain-
ing, 
GFP/IF 
staining 
-SMA/IF/EM 
8 week diet till 
20 weeks of 
age 
NA 
58% or 42% 
LacZ
+ or GFP
+ 
respectively of 
lesional SMC 
Sata et al. [3] 
Mechanical vascular 
injury 
      
 
Wire-mediated endo-
vascular injury 
LacZ/X-
gal stain-
ing, 
GFP/IF 
staining 
-SMA/IF, 
confocal  4 weeks  NA 
26% of neointi-
mal SMC, 35% 
of medial SMC 
Tanaka et al. 
[5] 
 
Perivascular cuff 
LacZ/X-
gal stain-
ing, 
GFP/IF 
staining 
-SMA/IF, 
confocal  4 weeks  NA  A few neointimal 
SMC 
Tanaka et al. 
[5] 
 
Ligation of carotid 
artery 
LacZ/X-
gal stain-
ing, 
GFP/IF 
staining 
-SMA/IH/IF, 
confocal  4 weeks  NA  A few neointimal 
SMC 
Tanaka et al. 
[5] 
  Scratch injury  Y-chr/ISH  -SMA/IH 4  weeks  NA  44% of neointi-
mal SMC 
Han et al. [31] 
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Table 1. Contd…. 
Experimental Study  Technique  Method to Determine  Time  Results  Reference 
  
SMC 
Origin 
SMC 
  Origin of 
Neointi-
mal SMC 
BM-Derived 
SMC 
 
 
Arterial thrombus by 
insertion of suture 
into artery 
Y-chr/ISH  -SMA/IH 4  weeks  NA 
None in arteries 
with minimal 
damage. Some 
BM-derived 
SMC in arteries 
with serious 
damage 
Han et al. [31] 
 
Wire-mediated endo-
vascular injury 
GFP/IF 
staining 
-SMA/IF, 
confocal  4 weeks  NA 
HSC did not 
contribute to 
neointimal SMC. 
BM and KSL 
cells did contrib-
ute partly to 
intimal and me-
dial SMC 
Sahara et al. 
[32] 
rat             
 
Stent implantation 
R26-
hPAP/IH, 
IF, confo-
cal 
-SMA/IF, 
confocal  4 weeks  NA  None  Groenewegen 
et al. [38] 
 
Aortic transplantation 
R26-
hPAP/IH, 
IF, confo-
cal 
-SMA/IF, 
confocal  2 months  NA  None  Groenewegen 
et al. [38] 
human        
 
Coronary artery athe-
rosclerosis 
Y-
chr/ISH, 
blood type 
A, IH 
-SMA 
10 years/90 
days 
(n=2) 
NA  In one patient 
possibly in media 
Yokote et al. 
[42] 
 
Coronary artery athe-
rosclerosis 
Y or X-
chr/ISH 
-SMA/IH 
Between 41 
and 1235 days 
(n=8) 
NA 
9.4% of intimal 
cells in females, 
10.8% in males 
Caplice et al. 
[41] 
Y-chr, Y-chromosome; X-gal, X-galactosidase; hPAP, human placental alkaline phophatase; ISH, in situ hybridization; IH, immunohistochemistry; 
IF, immunofluorescence; EM, electron microscopy; HSC, hematopoietic stem cells; KSL, c-Kit
+ Sca-1
+ Lin
- cells; NA, not available   
  In a hyperlipidemia-induced atherosclerotic mouse 
model, Sata et al. [3] showed that BM cells can be detected 
in atherosclerotic plaques. ApoE
-/- mice were transplanted 
with either GFP
+ or LacZ
+ BM cells and fed a high fat diet 
for eight weeks. A significant amount of -SMA
+  cells in 
atherosclerotic plaques were GFP
+ (40%) or LacZ
+ (60%) 
respectively. Such BM contribution to atherosclerotic plaque 
composition could not be confirmed by Bentzon et al. [29]. 
In apoE
-/- mice that received BM from sex-mismatched GFP
+ 
apoE
-/- mice and were fed a high fat diet they observed not 
one single GFP
+ -SMA
+ cell in atherosclerotic plaques of 
mice at 20 or 32 weeks of age. The same authors reported 
that in a model of plaque healing after spontaneous and me-
chanical plaque disruption in apoE
-/- mice, healing SMC 
were of local and not of blood origin [30].  
  Mechanical vascular injury leads to vascular remodeling 
involving accumulation of SMC at the site of injury. Studies 
have reported the contribution of BM cells to neointimal 
hyperplasia in this type of vascular disease [5, 31, 32]. In an 
elegant study by Tanaka et al. [5], the contribution of BM 
cells was investigated in a variety of mechanical vascular 
injury models. It was concluded that BM cells contribute to 
SMC accumulation caused by wire-mediated endovascular 
injury. Interestingly, Tanaka et al. [5] showed in two addi-
tional mechanical injury models that only a few BM cells 
were -SMA
+ in neointima after perivascular cuff placement 
and ligation of common carotid artery. Notably, BM cells 
were abundant in the neointima and media after carotid liga-
tion, yet further characterization of these cells was not per-
formed. Consistent with these results [5], it was reported that 
in a scratch injury model 56% of the neointimal cells was 
BM-derived of which 44% were SMC [31]. Moreover, Sa-
hara et al. [32] showed the contribution of different BM cell 
populations after wire-mediated vascular injury. Total BM 
(TBM) cells, c-Kit
+ Sca-1
+ Lin
- (KSL) cells, or highly puri-
fied hematopoietic stem cells, expressing GFP, were trans-
planted into irradiated mice before injury. TBM and KSL 
cells could give rise to vascular cells and therefore contrib-
uted to neointimal and medial SMC after vascular injury. 
However, this did not occur in the group of mice that re-
ceived a purified population of hematopoietic stem cells as 
hardly any GFP
+ cells were detected in the lesions.  
  The variable results in studies investigating the role of 
BM in vascular disease suggest that the origin of intimal Smooth Muscle Progenitor Cells  Current Stem Cell Research & Therapy, 2009, Vol. 4, No. 2      135 
cells is diverse and that the mode or severity of injury can 
determine the contribution of BM-derived cells to neointimal 
SMC. Besides the differences in the pathogenesis of the em-
ployed experimental models, differences in methodology 
could explain in part the conflicting conclusions. Severity of 
injury may play a major role in the recruitment process of 
BM cells. Wire injury is known to induce complete endothe-
lial denudation and medial cell loss as a result of apoptosis 
whereby the subsequent expression of growth factors may be 
important for the involvement of BM-derived cells [3, 33]. 
BM transplantation involving lethal irradiation followed by 
exogenous transplantation of BM cells could affect the in-
volvement of BM cells in vascular remodeling. Indeed, it 
was recently described that BM transplantation had suppres-
sive effects on neointima formation after wire injury [34]. 
Furthermore, although BM origin of neointimal SMC could 
not always be confirmed, BM cells may contribute to other 
cell populations in the neointima [3, 5, 26, 31]. Evidently, 
the role of BM-derived SPC is far from understood and fu-
ture studies will shed more light on its involvement in vascu-
lar disease.  
  The adventitial layer potentially harbors a population of 
stem cells that can also contribute to vascular remodeling. 
Hu et al. [35] demonstrated that abundant progenitor cells in 
the adventitia can differentiate into SMC that participate in 
lesion formation in vein grafts. This is supported by a study 
which recently reported that the adventitial layer possesses a 
niche of stem cell antigen (sca-1)
+ SPC. Moreover, this 
population of progenitor cells differentiated into SMC-like 
cells ex vivo [36]. Progenitor cells have also been detected in 
the medial layer of the vessel wall. Progenitor cells isolated 
from the tunica media of mouse aortas by flow cytometry 
could acquire the phenotype of SMC in culture as measured 
by positivity for calponin, -SMA and SM MHC [37]. The 
possibility of a stem cell niche in the vessel wall could be of 
importance in studies that report a non-BM-derived origin 
for cells in the neointima [5, 25-27, 29, 30, 38].  
  Human data on the origin of SMC in vascular disease is 
valuable yet scarce. Studies have described the detection of 
recipient cells in donor vessels after female to male organ 
transplantation. Grimm et al. [39] reported the presence of 
recipient cells in the vascular and interstitial compartments 
of renal allografts after female to male renal transplantation. 
Furthermore, Quaini et al. [40] showed a high number of 
recipient cells in eight hearts that were transplanted from 
females to males. Until now, one study has shown that sex-
mismatched BM transplant subjects can have BM-derived 
SMC throughout the atherosclerotic vessel wall. Extensive 
recruitment of BM cells in diseased and not in undiseased 
segments was demonstrated and cell-cell fusion events were 
excluded as a cause for this enrichment [41]. In contrast, 
Yokote et al. [42] examined coronary artery autopsy speci-
mens of two individuals who had undergone allogenic BM 
transplantation to determine the origin of vascular SMC in 
the vessel wall. None of the intimal SMC were of BM origin, 
yet in one individual donor-derived -SMA
+ cells were de-
tected in the media. The difference in underlying disease 
states of the patients may be the cause of the contradictory 
results. These studies suggest that BM progenitor cells may 
also play a role in human neointima formation.  
Debatable Issues for BM-Derived Cell Characterization 
  A number of issues are controversial regarding the 
method by which BM cells are characterized. One of these 
issues regards the detection method of BM cells that express 
SMC markers in BM-chimeric animals. In these animals, 
BM cells are usually labeled with LacZ, GFP or are sex-
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Contribution of BM cells to neointima after vascular injury or graft transplantation. BM cells in donor grafts or after vascular injury 
can be identified by immunohistochemistry, immunofluorescence or in situ hybridization for GFP, LacZ, or Y-chromosome and -SMA. 
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mismatched. The specificity of co-localizing techniques such 
as low resolution immunomicroscopy to assess the origin of 
cells in BM-chimeric animals has been questioned. In view 
of this, a high-resolution confocal microscopy with Z-axis 
analysis has been employed to convincingly demonstrate that 
BM-derived cells express -SMA in neointima after wire-
mediated vascular injury [5]. On the other hand, Bentzon et 
al used this microscopy technique in a hyperlipidemia-
induced atherosclerotic mouse model and showed no colo-
calisation of BM and SMC [29, 30]. High-resolution electron 
microscopy is another technique which has been used to con-
firm the presence of BM-derived SMC [3, 5]. Furthermore, 
to avoid the use of GFP antibodies which can potentially 
increase the risk of false signals by nonspecific antibody 
binding, studies have applied a plastic embedding technique 
of arteries to preserve endogenous GFP-fluorescence signal 
[5, 32].  
  Another debatable issue is the choice of markers to iden-
tify intimal SMC. -SMA is widely used in most studies to 
identify SMC as it is considered a sensitive marker for SMC. 
However,  -SMA is not a definitive SMC lineage marker 
and has been reported to be expressed by many lineages 
other than SMC [1]. More specific markers including SM 
MHC, calponin, SM22, caldesmon and smoothelin may fur-
ther confirm SMC presence. Nevertheless, whether intimal 
SMC, and more importantly, BM-derived neointimal SMC 
express these markers typical of “contractile” SMC is not 
clear.  
  Much effort has been devoted to targeting migration and 
proliferation of medial SMC, yet to date no effective therapy 
exists. Investigation into the origin of SMC and the mecha-
nisms that alter SMC phenotype will potentially shed light 
onto mechanisms that drive pathological arterial remodeling. 
Discrepancies still remain in interpretation of in vitro and in 
vivo data as different animal models, methodology and cell 
markers are used. Particularly, this must be kept in mind 
when extrapolating data to the human condition as patholo-
gies differ.  
Complex Role of Circulating SPC in Health and Disease 
  SMC can exhibit a wide range of phenotypes in response 
to changes in the local environment. Due to this plasticity, 
selecting unique markers that can identify SMC at different 
stages of differentiation, particularly in relation to vascular 
disease, is complex. This complexity is reflected in the de-
termination and characterization of circulating progenitors 
for SMC and is experimentally challenging.  
  In healthy conditions, SPC have been cultured from the 
mononuclear cell fraction of human peripheral blood in se-
lection medium supplemented with platelet-derived growth 
factor (PDGF)-BB. Simper et al. [43] described for the first 
time the rapid outgrowth and expansion of SPC that were 
positive for -SMA, SM MHC, and calponin. Furthermore, 
integrin 51 expression was increased and facilitated adhe-
sion to extracellular matrix protein fibronectin. In a follow-
ing study, the integrin profile of SPC in human peripheral 
blood was studied in more detail, as well as their adhesion to 
extracellular matrix in vitro. Moreover, injection of SPC into 
porcine coronary arteries showed that SPC can adhere in vivo 
to fibronectin-coated mesh stents [44]. Other culture condi-
tions such as using collagen-coated plates or media supplem-
tented with growth factors such as transforming growth fac-
tor (TGF-), fibroblast growth factor (FGF) and insulin-like 
growth factor (IGF) have also been used to identify a SPC 
population in the mononuclear cell fraction of peripheral 
blood [45, 46].  
  Circulating SPC have been identified in different disease 
states. In patients with type 1 diabetes, the number of colla-
gen- and -SMA- expressing SPC was increased after seven 
days of culture indicating a possible role in adverse tissue 
remodeling [47]. In peripheral blood of patients with coro-
nary artery disease (CAD), circulating cells expressing 
CD14, CD105 and -SMA
 were increased compared to non-
CAD patients [45]. This shows a potential role for SPC in 
the pathogenesis of vascular disease. In addition, it was re-
ported that in patients with atherosclerotic CAD, the number 
of peripheral CD34
+ cells was increased one day after a 
stenting procedure which was independently predictive of in-
stent restenosis [48]. Although the above mentioned studies 
identify circulating SPC both in healthy and disease condi-
tions, they do not elucidate the potential biological relevance 
and actual contribution to vascular disease. Until now, one 
study has investigated the direct role of circulating SPC in 
atherosclerosis. Zoll et al. [49] reported that injection of hu-
man SPC, cultured from the mononuclear cell fraction of 
peripheral blood, into immune-deficient atherosclerotic-
prone mice was able to limit plaque development and pro-
mote changes in plaque composition towards a stable pheno-
type. It is not clear from this study how SPC injection ex-
erted these effects but possibilities include the incorporation 
of SPC themselves into the plaque or secretion of growth 
factors that stimulate local SMC and collagen synthesis. 
They also investigated SPC levels in patients with acute 
coronary syndrome compared to patients with stable angina. 
Blood-derived SPC were cultured for five weeks after which 
expression of SMC markers was analyzed. SPC levels in 
patients with acute coronary syndrome were reduced com-
pared to stable angina patients suggesting that reduced SPC 
levels might play a role in plaque destabilization. Although 
the above-mentioned conflicting results may in part be due 
to differences in methods to identify circulating SPC, there is 
an indication for both beneficial as well as adverse roles for 
SPC. This may depend on the severity and cause of vascular 
injury, the presence of cardiovascular risk factors [47] and 
stage of atherosclerosis. At the early onset of atherosclerosis 
SMC contribute to intimal thickening, however, in advanced 
atherosclerosis, when a plaque consists of a large lipid core 
with an inflammatory component and a thin fibrous cap, 
SMC play a major role in the maintenance of plaque stability 
[9]. Therefore, SPC could be beneficial in atherogenesis as a 
factor promoting plaque stability and can thus be considered 
a ‘friend’ in vascular disease. In contrast, involvement of 
SPC in neointima formation highlights a detrimental role for 
SPC as ‘foe’ in vascular disease. 
  In peripheral blood of mice, a variety of markers have 
been used to identify SPC. One day after arterial injury, Zer-
necke et al. [50] found that the number of c-kit
-/lin
-/PDGF 
receptor (R)-
+/sca-1
+  cells was increased in peripheral 
blood. Furthermore, these cells were able to differentiate into 
SMC in response to PDGF-BB in vitro and respond to stro-
mal cell-derived factor (SDF)-1 – mediated recruitment and 
differentiation into neointimal SMC in vivo. This was con-
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which a peak in number of sca-1
+/lin
-/c-kit
- cells was seen in 
peripheral blood one week after injury and the number of 
sca-1
+  cells in the adventitia was increased at time points 
coinciding with neointima formation [51]. Other studies have 
confirmed the presence of a sca-1
+ stem cell population in 
the adventitia which are able to differentiate into SMC in the 
presence of PDGF-BB [35, 36].  
  Besides peripheral blood, BM stromal cells are also able 
to differentiate into SMC in vitro [52]. A unique cell popula-
tion was isolated from the adhesion fraction of BM cells 
based on expression of GFP that was driven by the SM22 
promotor. These cells expressed PDGFR- but neither ma-
ture nor immature SMC-specific proteins. By following the 
longitudinal transition of their phenotypes, it was found that 
they eventually differentiated into SMC as measured by ex-
pression of calponin, SM1 and -SMA. Several studies indi-
cate a role for PDGF in SPC differentiation and characteriza-
tion [50]. The recruitment of BM cells that are able to differ-
entiate into SMC, to perivascular sites in tumors [53] is de-
pendent on PDGF-PDGFR- signaling. Moreover, it is of 
importance in recruitment of SMC during blood vessel for-
mation in the mouse [54].  
  Identification and characterization of SPC in tissue and in 
culture is a field of research that is just at the beginning of 
exploration. Many markers are not unique for different SMC 
phenotypes, which results in hurdles when applying this 
knowledge to the SPC field. Extensive characterization of 
SPC is required to evaluate their contribution to vascular 
remodeling and potential as a therapeutic target.  
SPC AS A THERAPEUTIC TARGET IN VASCULAR 
DISEASE 
  SMC accumulation is a key event in neointima formation 
during atherosclerosis, restenosis and transplant arterioscle-
rosis. Inhibition of the contribution of SPC in neointima may 
therefore be a possible target for prevention of vascular dis-
ease. However, SMC accumulation in fibrous cap formation 
is desirable for plaque stability indicating a potential benefi-
cial role for SPC. Although the exact role of SPC in vascular 
remodeling is not clear, a number of signaling pathways 
have been reported to be of importance in SPC recruitment 
and homing. This may be relevant when considering influ-
encing the involvement of SPC in vascular disease.  
 SDF-1 is a CXC chemokine which is essential in regu-
lating hematopoietic progenitor cell mobilization [55, 56]. 
The importance of SDF-1 and its receptor CXCR4 has been 
shown in recruitment of progenitor cells in vascular remodel-
ing. SDF-1 can play a role in neointima formation by regu-
lating neointimal SMC content [57]. Moreover, the expan-
sion of circulating PDGFR-
+/sca-1
+/lin
- progenitor cells in 
the peripheral blood of apoE
-/- mice following arterial injury 
is mediated by SDF-1. Regarding the receptor of SDF-1, 
CXCR4 plays a pivotal role in this process as repopulation of 
apoE
-/- mice with CXCR4
-/- BM display a reduction in neoin-
timal hyperplasia linked to a decrease in SMC content [50]. 
Interestingly, in a therapeutic setting, a CXCR4 antagonist 
can inhibit neointima formation and SPC mobilization after 
arterial injury [58]. Platelets may play an essential role in the 
SDF-1/CXCR4 axis as they can secrete SDF-1. Platelet 
adhesion to exposed subendothelium takes place after vascu-
lar injury and it has been shown that they can interact with 
progenitor cells [50, 59]. Inhibition of platelet adhesion, by 
inhibiting P-selectin, can abrogate adhesion of BM-derived 
progenitor cells at sites of endothelial disruption [59]. There-
fore, platelet-dependent mechanism of SDF-1-secretion 
could be essential in the involvement of SPC in arterial re-
modeling.  
  Other factors have also been implicated in SDF-1 ex-
pression. Endothelial nitric oxide synthase (eNOS)-
deficiency can increase SPC in association with upregulation 
of SDF-1 in arterial injury indicating an additional protec-
tive role of nitric oxide in vascular disease [51]. Further-
more, expression of the transcription factor hypoxia-
inducible factor (HIF)-1 in injured arteries can control 
SDF-1-mediated neointimal formation in apoE
-/- mice [60]. 
HIF-1 can induce SDF-1 expression resulting in an in-
crease in adhesion, migration and homing of circulating 
CXCR4
+ progenitor cells to ischemic tissue [61]. Moreover, 
depletion of phosphatase and tensin homology deleted on 
chromosome 10 (PTEN), a lipid phosphatase in SMC, results 
in HIF-1-mediated production of SDF-1 in SMC. This can 
induce progenitor cell migration through a paracrine signal-
ing mechanism. PTEN antagonizes phosphatidylinositol 3-
kinase-mediated signaling events, resulting in an inhibitory
 
effect on neointima formation in a
  carotid arterial balloon 
injury model [62]. Potentially, PTEN could thus be a target 
for inhibition of vascular remodeling [63]. 
  In a clinical setting, current therapeutic strategies have 
been investigated regarding their role in SPC accumulation 
in neointima formation. Rosiglitazone, a peroxisome prolif-
erator-activated receptor- (PPAR-) agonist, can inhibit 
intimal hyperplasia after balloon injury [64, 65]. This could 
be through promoting differentiation of progenitor cells to-
wards the endothelial lineage and inhibiting differentiation 
towards the SMC lineage [66]. Similarly, sirolimus, which is 
used on stents to prevent in-stent restenosis, could attenuate 
the number of BM-derived SPC in lesions in a vascular in-
jury model [67]. The same group reported that angiotensin II 
could accelerate, whereas the blocker of angiotensin II type 1 
receptor suppressed neointima formation after arterial injury 
which correlated with the number of BM-derived SMC in 
the lesions [68].  
  Besides modulating differentiation of progenitor cells 
towards an endothelial phenotype, there may be a potential 
dual role for SPC in vascular disease which can be targeted. 
Until recently, it was thought that SPC have a detrimental 
role as a contributor to SMC accumulation in vascular dis-
ease. However, as described recently [49], SPC may be in-
volved in plaque stability at advanced stages of atherosclero-
sis. Therefore one can imagine that targeting SPC to plaques 
in patients with advanced atherosclerosis can decrease the 
risk of plaque rupture. Indeed, it has been suggested that a 
deficiency in SPC could represent a novel risk factor in pa-
tients with CAD [49]. This indicates a role for SPC on the 
one hand as a ‘friend’ in an advanced stage of atherosclerosis 
and on the other hand as a ‘foe’ in restenosis after mechani-
cal vascular injury and transplant arteriosclerosis (Fig. 2).  
CONCLUSION 
  Current animal and human data suggest that BM-derived 
SPC can give rise to SMC and participate in neointima for-
mation. Signaling pathways involved in SPC differentiation, 138    Current Stem Cell Research & Therapy, 2009, Vol. 4, No. 2  Oostrom et al. 
recruitment and homing are starting to be elucidated and 
cardiovascular pharmacological interventions can be devel-
oped to influence these processes. The exact role of SPC in 
the neointima is not clear and may differ depending on the 
cause and severity of vascular injury, stage of atherosclerotic 
disease and the presence of certain cardiovascular risk fac-
tors. These aspects may modulate mobilization, incorpora-
tion and differentiation of BM-derived progenitor cells, lead-
ing to SPC as ‘foe’ in vascular disease. However, SPC may 
potentially be a ‘friend’ as inducers of plaque stability in 
certain stages of atherosclerosis. Studies investigating BM 
involvement in vascular disease will contribute significantly 
to the knowledge of SMC accumulation that may result in 
novel therapeutic tools that can target and prevent develop-
ment and progression of vascular disease.   
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